Reviewer's report

Title: Gli promotes tumor progression through regulating epithelial-mesenchymal transition in non–small-cell lung cancer

Version: 0 Date: 06 Nov 2019

Reviewer: Shuishen Zhang

Reviewer's report:

Presentation and writing of this manuscript is good and clear. Jiang et al found that aberrant upregulation of the Gli signaling pathway and a strong association between expression of Gli versus AKT and EMT markers in NSCLC. This is the article are important to those with closely related research interests. The results of the manuscript are interesting. But here are still some main remarks which need to be revised for this manuscript being accepted:

Major:

1. In Result section, authors found that Gli was upregulated and associated with AKT and EMT pathway markers in NSCLC tissue samples. Here, they just showed figure 1 about western blotting. I wondered whether any statistical analysis evidence to prove it and show us.

2. The expression of Gli was proved to be associated with EMT markers expression in 36 matched NSCLC and normal patient tissue samples. Besides, Gli inhibition and siRNA knockdown reduces EMT, cell viability in vitro. Is there any possibility that the expression of Gli associates with the lymph node metastasis of these 36 NSCLC patients?

Minor

1. This article presented so many figures where there are some figures should be combined. Figure 3 and 4, Figure 5 and 6, Figure 7 and 8 should be presented in one big figure, respectively.

Level of interest
Please indicate how interesting you found the manuscript:

An article whose findings are important to those with closely related research interests

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable
**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal